Luke Halpern, Assistant Editor

There was a detrimental relationship between COVID-19 caseload and mortality observed across multiple types of hospitals.

Poorer prognosis was linked to factors such as reduced hemoglobin levels and advanced stage at diagnosis.

Although the investigators commonly detected treatment-emergent resistant variants, they were rare and transient in nature.

Alan Corley, pharmacy owner in Greenville, TN, reflects on the changes he's witnessed throughout his career and the most rewarding aspects of his profession.

These interim trial results support the ongoing phase 3 ITHACA trial.

Promising depth of response and consistent safety profile support the use of talquetamab as a combination agent.

Although disease screening reached high-risk patients, uptake was low, necessitating additional incentive to participate in voluntary testing.

These results indicate the combination’s long-term effectiveness in a population with limited treatment options.

The approval marks the only FDA-approved stand-alone therapy for the treatment of Niemann-Pick disease type C (NPC).

Long-term shedding of mutated variants could pose a concern for spread among the public.

As the end of the DSCSA stabilization period approaches, Josh Bolin from the NABP provides an overview of what to expect.

Childhood immunization according to schedule can prevent serious illness.

Further trials are required to examine the long-term feasibility of intravenous immunoglobulin (IVIG) for multisystem inflammatory syndrome.

Approved with 3 new indications, bimekizumab-bkzx is the first and only interleukin-17 inhibitor approved for these diseases.

As the end of this Congress approaches, the National Community Pharmacists Association is lobbying members to pass pharmacy benefit manager reforms.

Three of the largest pharmacy benefit managers ––Express Scripts, Optum, and Caremark––are listed in the suit.

The rare disease can result in progressive neurological symptoms and organ complications.

Improvements in survival outcomes were seen among those at high risk for DLBCL who received 6x R-CHOP21 + 2R.

Though hospitalizations and test positivity remain at modest levels, wastewater analysis indicates high circulation of SARS-CoV-2, especially in western states.

In a patient with long-shedding SARS-CoV-2, transfusion-related acute lung injury developed after intravenous immunoglobulin, emphasizing careful treatment considerations.

In 2021, cancer diagnosis rates remained low after major disruptions during the first year of the COVID-19 pandemic.

The non-opioid drug can induce healing of joint cartilage in patients with osteoarthritis.

Abstracts from the OrigAMI-1 and MARIPOSA-2 trials indicated the treatment benefits of amivantamab-vmjw and chemotherapy in multiple cancer indications.

In the absence of a common treatment for long COVID, researchers from around the world documented the best currently available therapies.

Subcutaneous administration of atezolizumab and hyaluronidase-tqjs had similar efficacy to intravenous administration.

These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.

Promising abstracts surrounding DLL3 targeting for patients with lung and neuroendocrine cancer were presented at WCLC 2024.

Highlights from multiple trials investigating novel treatments for mNSCLC were presented at 2024 World Conference on Lung Cancer.

Tocilizumab reduced relapses in 4 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

When IVIG was administered within 48 hours of hospital admission, hospital and ICU length of stay were dramatically shortened.